Loading...
•
Mar 31, 2024
Fate Therapeutics Q1 2024 Earnings Report
Reported business highlights and financial results.
Key Takeaways
Fate Therapeutics reported its Q1 2024 financial results, including revenue of $1.9 million and cash, cash equivalents, and investments of $391.1 million. The company also made progress across three key areas of clinical focus with FT819, FT522 and FT825 programs.
First lupus patient was treated with FT819 CAR T-cell product candidate in Phase 1 autoimmunity study; future clinical development of FT819 to focus exclusively on autoimmune disease.
Enrollment was initiated with FT522 CAR NK Cell product candidate in conditioning-free treatment arm of Phase 1 B Cell Lymphoma Study.
First patient was treated with FT825 / ONO-8250 CAR T-cell product candidate in Phase 1 solid tumor study.
The company has $391 million in cash, cash equivalents, and investments.
Revenue by Segment
Forward Guidance
Fate Therapeutics plans to expand clinical development in autoimmunity with its off-the-shelf FT819 and FT522 programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...